Search Results  for '4174.TWO'

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

OBI Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

25 Jun 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - OBI Pharma Inc (4174-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

26 Jun 2016 Thomson Reuters Stock Report 11 $25.00

OBI Pharma (4174 TT, Neutral) No surprises during latest analyst meeting

[Distributed earlier to SinoPac clients prior to JUN 20 trading session] OBI Pharma (4174 TT, Neutral) No surprises durin...

20 Jun 2016 SinoPac Sec Inv Service 6 $23.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical company. The...

15 Jun 2016 GlobalData 34 $300.00

OBI Pharma Inc. (4174 TT); Diamond Shines on International Stage

OBI’s stock prices encountered headwinds after the results of unblinding released on February 21st, due to market skepticism ...

07 Jun 2016 MasterLink Securities Corporation 8 $81.00

浩鼎 (4174):越磨越亮,終將發光

烏雲散去,未來雖仍有眾多挑戰,然元富正面看待,重申買進評等:浩鼎評價在2/21解盲後遭受眾多基本面因素干擾而受到壓抑,造成市場誤解;然ASCO於5/19公布浩鼎OBI-822論文摘要,在臨床數據獲得驗證下,浩鼎已獲得平反,元富亦於5/20調升至買進評...

05 Jun 2016 MasterLink Securities Corporation 7 $58.00

Thomson Reuters Stock Report - OBI Pharma Inc (4174-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 11 $25.00

OBI Pharma Inc. (4174 TT): ASCO Accepted OBI’s Data Submission

OBI unblinded its OBI-822 Phase 2/3 clinical trials in TPEx on February 21st, 2016, and OBI-822 did not show a statistically ...

07 Apr 2016 MasterLink Securities Corporation 8 $81.00

浩鼎 (4174):踏出一步,ASCO接受浩鼎申請

回歸生技產業發展,尊重學術專業,靜待6/3 ASCO數據發表:浩鼎在2/21於櫃買中心公布其解盲未達主要療效指標統計意義後,由於浩鼎須遵從ASCO規範不得提前公布數據,亦產生眾多非基本面議論,進而使評價受到影響,亦連帶影響其他生技醫療類股。基於風險考...

31 Mar 2016 MasterLink Securities Corporation 7 $58.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical company. The...

16 Mar 2016 GlobalData 38 $300.00